Title: Relationship of Dr. Reddy Laboratory Ltd. With Nifty 50.
Author: Divya Kakade
Introduction:
Dr. Reddy’s Laboratories Ltd. is a leading Indian multinational pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company specializes in the manufacturing and distribution of generic medicines, active pharmaceutical ingredients (APIs), and proprietary products across global markets. With a strong focus on research and innovation, Dr. Reddy’s operates in over 50 countries, catering to therapeutic segments such as oncology, gastroenterology, and cardiovascular diseases. The company is a key constituent of the Nifty 50 index, reflecting its significant impact on the Indian stock market and the pharmaceutical sector.
Objective:
To find out β (Beta) of the company and its significance.
Literature Review:
1. Indexing CNX NIFTY 50 Momentum Effects
Misra and Mohapatra (2015) investigate the momentum effect within the CNX NIFTY 50 index, analysing whether stocks that have performed well in the past continue to outperform, while underperforming stocks persist in their downward trajectory. The study applies empirical methodologies, including risk-adjusted return analysis and regression models, to determine the profitability of momentum-based investment strategies. Their findings indicate that investors can generate excess returns by leveraging momentum strategies, suggesting that the Indian stock market is not entirely efficient. Given that Dr. Reddy’s Laboratories Ltd. is a key component of the Nifty 50 index, the study highlights how pharmaceutical stocks, including defensive stocks like Dr. Reddy’s, may exhibit unique momentum characteristics, especially during different market cycles.
2. The Behaviour of Extreme and Cumulative Stock Price Random Variables during Crisis Periods—A Study of Nifty 50 Stocks
Gali (2021) examines how extreme and cumulative stock price movements of Nifty 50 stocks, including Dr. Reddy’s Laboratories Ltd., behave during financial crises. The study employs statistical models such as extreme value theory and volatility clustering techniques to assess the resilience of Nifty 50 stocks during market downturns. The results suggest that pharmaceutical companies, including Dr. Reddy’s, tend to perform relatively well during crises due to their defensive nature and consistent demand for healthcare products. The study also identifies patterns in volatility and stock price recovery, highlighting how macroeconomic shocks impact individual stock performance. These insights provide a deeper understanding of Dr. Reddy’s role within the Nifty 50, particularly in terms of risk mitigation and long-term stability.
Data Collection:
For data collection Dr. Reddy Laboratories Limited and Nifty 50 data was downloaded from NSE site for the period 01-01-2024 to 31-12-2024. The data was manipulated for finding the closing price, weekly returns were calculated. Weekly returns of Nifty 50 were considered as ‘x’ and weekly returns at company were considered as ‘y’. Y was regressed on X.
Data Analysis:
Equation: Dr. Reddy’s Lab = -0.0086657 – 5.22614 Nifty50
Interpretation: The regression equation describes the relationship between Nifty50 (X) and Dr. Reddy’s Lab share price (Y), indicating that Dr. Reddy’s Lab’s share price is the dependent variable, while Nifty50 is the independent variable. The negative coefficient of -5.22614 suggests that for every unit increase in Nifty50, Dr. Reddy’s Lab share price is expected to decrease by 5.22614 units. With 47 observations, the value is 0.107408, implying that approximately 10.74% of the variation in Dr. Reddy’s Lab’s share price can be explained by changes in Nifty50. The F-value for the model is 5.41. The p-value for the slope is 0.024523, which is less than the conventional threshold of 0.05. This indicates that the relationship between Nifty50 and Dr. Reddy’s Lab’s share price is statistically significant at the 5% level. Consequently, this model provides evidence to suggest a significant linear relationship between Nifty50 and Dr. Reddy’s Lab’s share price.
Conclusion:
β (Beta) is -5.22 indicates that it is highly volatile and moves in the opposite direction of the market. Such negative beta suggests that the stock could act as a hedge against markets movements.
References:
1. Arun Kumar Misra & Sabyasachi Mohapatra, 2015. “Indexing CNX NIFTY 50 Momentum Effects,” Margin: The Journal of Applied Economic Research, National Council of Applied Economic Research, vol. 9(2), pages 157-178, May.
2. Srilakshminarayana Gali, 2021. “The Behaviour of Extreme and Cumulative Stock Price Random Variables during the Crisis Periods-A Study of Nifty 50 Stocks,” Economic Research Guardian, Mutascu Publishing, vol. 11(1), pages 103-129, June.